RepligenRGEN +9.50%83 Median PS Value is $179.88 as of Jun. 24, 2026, which is 11431% above its 10-year median of 1.56. GuruFocus rates RGEN with a GF Score™ of 83/100 and a GF Value™ of $175.89 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 337 Medical Devices & Instruments companies, Repligen ranks worse than 50.15% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Repligen's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $13.487. Repligen's 10-Year median PS Ratio is 13.3373. Therefore, the Median PS Value for today is $179.88.
As of today (2026-06-24), Repligen's share price is $138.40. Repligen's Median PS Value is $179.88. Therefore, Repligen's Price to Median PS Value for today is 0.77.
The historical rank and industry rank for Repligen's Median PS Value or its related term are showing as below:
RGEN'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.65 Med: 1.56 Max: 2.58
Current: 0.77
During the past 13 years, the highest Price to Median PS Value of Repligen was 2.58. The lowest was 0.65. And the median was 1.56.
RGEN's Price-to-Median-PS-Value is ranked worse than 50.15% of 337
companies
in the Medical Devices & Instruments industry
Industry Median: 0.7
vs RGEN: 0.77
Repligen (NAS:RGEN) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Repligen's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
138.40
/
179.88
=
0.77
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Repligen Median PS Value Related Terms
Repligen Median PS Value Historical Data
* Premium members only.
The historical data trend for Repligen's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGEN vs ATR, AVTR, TFX: Median PS Value Comparison
For the Medical Instruments & Supplies subindustry, Repligen's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Repligen Price-to-Median-PS-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Repligen's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 13.3373.
Repligen's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.487.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Repligen (RGEN) has a Median PS Value of $179.88 as of Jun. 24, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Repligen and its competitors. This is 11431% above median its historical median of 1.56. Over the past decade, Repligen's Median PS Value has ranged from 0.65 to 2.58. According to the industry distribution chart, Repligen ranks #169 out of 337 companies in the Medical Devices & Instruments industry, placing it in the top 50.1%.
Is Repligen's Median PS Value too high?
Repligen's current Median PS Value of $179.88 is 11431% above median its 10-year median of 1.56. Over the past 10 years, this metric has ranged from a low of 0.65 to a high of 2.58. The Medical Devices & Instruments industry median Median PS Value is 0.70. Repligen's value of $179.88 is 25597.1% above this industry median. Based on the distribution chart, Repligen ranks #169 out of 337 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Repligen has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Repligen's Median PS Value compare to ATR and AVTR?
According to the Medical Devices & Instruments industry distribution chart, Repligen ranks #169 out of 337 companies for Median PS Value. This places Repligen in the lower half of its industry. The industry median Median PS Value is 0.70. Repligen's value of $179.88 is 25597.1% above this benchmark. Historically, Repligen's own Median PS Value has ranged from 0.65 to 2.58 over the past decade. While the company's 10-year median is 1.56 vs. the industry median of 0.70, Repligen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Devices & Instruments company?
The median Median PS Value among Medical Devices & Instruments companies is 0.70, based on 337 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Repligen's current Median PS Value of $179.88 is 25597.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Repligen and its competitors. For the Medical Devices & Instruments industry, the median Median PS Value is 0.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Repligen's current Median PS Value is $179.88, which is 11431% above median its own 10-year median of 1.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repligen stock overvalued right now?
Based on GuruFocus' analysis, Repligen (RGEN) is currently considered Modestly Undervalued. The stock's GF Value™ is $175.89, compared to a current price of $138.40 — trading 21.3% below its estimated fair value. The current Median PS Value is $179.88, which is 11431% above median its 10-year median of 1.56 and 25597.1% above the Medical Devices & Instruments industry median of 0.70. Repligen's overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Repligen (RGEN), the current Median PS Value is $179.88 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Repligen (RGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Repligen stock appears to be undervalued.
The current stock price of $138.40 is trading 21.3% below its estimated GF Value™ of $175.89.
GuruFocus considers Repligen to be Modestly Undervalued.
Key valuation signals for RGEN:
Median PS Value: $179.88 (11431% above median its 10-year median of 1.56)
GF Value™: $175.89 vs. price of $138.40 (21.3% below fair value)
Industry Position: 25597.1% above the Medical Devices & Instruments median (#169 of 337)
No single metric tells the full story. See the RGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
83GF Score
Get the complete analysis for RGEN
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGEN has been successfully added to your 
